首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1898691

通用感染疾病治療市場規模、佔有率及成長分析（依疾病類型、治療類型、給藥途徑、最終用戶及地區分類）－2026-2033年產業預測

Zoonotic Disease Treatment Market Size, Share, and Growth Analysis, By Disease Type (Rabies, Lyme Disease), By Treatment Type (Vaccines, Antiviral Drugs), By Administration Route, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，通用感染疾病治療市場規模將達到 442.3 億美元，到 2025 年將達到 469.7 億美元，到 2033 年將達到 760 億美元，預測期（2026-2033 年）的複合年成長率為 6.2%。

市場分析顯示，通用感染疾病（即動物傳染給人類的疾病）每年影響眾多美國人，而都市化和人口成長加劇了這個問題。都市區衛生條件差進一步增加了患病風險。對動物性蛋白質的需求不斷成長，以及動物脂肪攝取量的增加，都可能增加通用感染疾病的風險。此外，寵物飼養的增加雖然帶來了陪伴，但也帶來了媒介傳播疾病的潛在健康風險。然而，發展中地區意識不足以及高昂的研發成本等挑戰可能會阻礙市場成長。儘管如此，針對動物健康需求的新型藥物的進步有望推動全球通用感染疾病治療市場投資和創新，從而促進市場成長。

通用感染疾病治療市場促進因素

通用感染疾病治療市場受多種因素驅動，包括人們對通用感染疾病流行情況及其傳播途徑的認知不斷提高。創新有效治療方法的推出，以及政府為對抗這些疾病所採取的支持措施，在市場擴張中發揮關鍵作用。此外，技術進步和研發投入的激增也顯著促進了市場成長。這些因素共同創造了一個充滿活力的環境，推動了通用感染疾病治療技術的進步，同時也凸顯了應對人畜共患病防控挑戰的緊迫性。

限制通用感染疾病治療市場的因素

儘管通用感染疾病治療市場具有巨大的成長潛力，但許多挑戰可能會阻礙其發展。主要因素包括有效治療方法方案有限、治療成本不斷上漲、研發投入不足。學名藥的出現和品牌藥專利到期可能會進一步減緩市場成長。此外，熟練專業人員短缺和醫療基礎設施不足，尤其是在開發中國家，也構成了該行業的障礙。研發所需的大量資金，加上民眾對通用感染疾病的認知不足，都對市場發展構成重大阻礙。

通用感染疾病藥物市場趨勢

受全球日益增強的防範意識和積極應對日益增多的通用感染疾病的舉措推動，通用感染疾病治療市場正經歷顯著成長。都市化、氣候變遷和棲地破壞等因素加劇了這些疾病的出現和傳播，促使人們增加對創新治療方法和疫苗研發及推廣的投資。此外，生物技術和基因工程的進步也帶來了更有效的治療方案。隨著醫療衛生系統將預防疾病爆發和控制通用感染疾病的影響作為優先事項，並加強公共衛生、製藥和環境機構之間的合作，預計該市場將顯著擴張。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

GlaxoSmithKline plc（UK）
Pfizer Inc.（USA）
Merck & Co., Inc.（USA）
Novartis AG（Switzerland）
Johnson & Johnson（USA）
F. Hoffmann-La Roche AG（Switzerland）
AstraZeneca plc（UK）
Bayer AG（Germany）
Eli Lilly and Company（USA）
AbbVie Inc.（USA）
Gilead Sciences, Inc.（USA）
Bristol-Myers Squibb Company（USA）
Takeda Pharmaceutical Company Limited（Japan）
Boehringer Ingelheim GmbH（Germany）
BioNTech SE（Germany）
Moderna, Inc.（USA）
Inovio Pharmaceuticals, Inc.（USA）
Emergent BioSolutions Inc.（USA）

結論與建議

簡介目錄

Product Code: SQMIG35I2117

Zoonotic Disease Treatment Market size was valued at USD 44.23 Billion in 2024 and is poised to grow from USD 46.97 Billion in 2025 to USD 76 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).

Market insights reveal that the incidence of zoonotic diseases transmitted from animals to humans affects a significant number of Americans annually, a concern exacerbated by urbanization and population growth. Poor sanitation in urban areas further heightens this risk. The rising demand for animal proteins may increase the risk of zoonotic infections due to higher consumption of animal fats. Additionally, pet ownership is on the rise, providing companionship but also introducing potential health risks from diseases carried by animals. However, challenges such as limited awareness in developing regions and high R&D costs may hinder market growth. Still, the global zoonotic disease treatment market stands to gain from advancements in novel medications tailored for animal health needs, paving the way for increased investment and innovation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Zoonotic Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Zoonotic Disease Treatment Market Segments Analysis

Global Zoonotic Disease Treatment Market is segmented by Disease Type, Treatment Type, Administration Route, End User and region. Based on Disease Type, the market is segmented into Rabies, Lyme Disease, Zika Virus, West Nile Virus, Hantavirus, Malaria, Tuberculosis, Relapsing Fever, Viral Hepatitis and Others. Based on Treatment Type, the market is segmented into Vaccines, Antiviral Drugs, Antibiotics, Immunoglobulins, Antibacterial Medication, Antifungal Medication and Others. Based on Administration Route, the market is segmented into Intravenous, Intramuscular and Oral. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Homecare Settings, Research Institutions and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Zoonotic Disease Treatment Market

The zoonotic disease treatment market is propelled by a variety of factors, including the growing prevalence of zoonotic diseases and heightened awareness regarding their transmission. The introduction of innovative and effective treatment options plays a crucial role in this market's expansion, alongside supportive government initiatives aimed at combating these diseases. Additionally, advancements in technology and a surge in research and development investments significantly contribute to market growth. Together, these elements create a dynamic environment that fosters progress in the treatment of zoonotic diseases, highlighting the urgent need to address the challenges associated with their management and prevention.

Restraints in the Zoonotic Disease Treatment Market

Despite the considerable growth potential in the Zoonotic Disease Treatment market, various challenges could impede progress. Key factors include the limited availability of effective treatment options, prohibitive treatment costs, and insufficient investment in research and development. The advent of generic medications and the expiration of patents on branded drugs may further slow market growth. Additionally, the industry confronts obstacles due to a shortage of skilled professionals and inadequate healthcare infrastructure, particularly in developing countries. High capital requirements for research and development, coupled with a lack of public awareness about zoonotic diseases, pose significant barriers to the market's advancement.

Market Trends of the Zoonotic Disease Treatment Market

The Zoonotic Disease Treatment market is experiencing notable growth, fueled by a surge in global awareness and proactive measures against the rising prevalence of zoonotic diseases. Factors such as urbanization, climate change, and habitat disruption are contributing to the emergence and spread of these diseases, prompting increased investment in research, development, and deployment of innovative treatments and vaccines. Additionally, advancements in biotechnology and genetic engineering are paving the way for more effective therapeutic solutions. As healthcare systems prioritize preventing outbreaks and managing zoonotic disease impacts, the market is poised for significant expansion, fostering collaboration between public health, pharmaceutical, and environmental entities.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Zoonotic Disease Treatment Market Size by Disease Type & CAGR (2026-2033)

Market Overview
Rabies
Lyme Disease
Zika Virus
West Nile Virus
Hantavirus
Malaria
Tuberculosis
Relapsing Fever
Viral Hepatitis
Others

Global Zoonotic Disease Treatment Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Vaccines
Antiviral Drugs
Antibiotics
Immunoglobulins
Antibacterial Medication
Antifungal Medication
Others

Global Zoonotic Disease Treatment Market Size by Administration Route & CAGR (2026-2033)

Market Overview
Intravenous
Intramuscular
Oral

Global Zoonotic Disease Treatment Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Ambulatory Surgical Centers
Homecare Settings
Research Institutions
Clinics

Global Zoonotic Disease Treatment Market Size & CAGR (2026-2033)

North America (Disease Type, Treatment Type, Administration Route, End User)
- US
- Canada
Europe (Disease Type, Treatment Type, Administration Route, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disease Type, Treatment Type, Administration Route, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disease Type, Treatment Type, Administration Route, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Disease Type, Treatment Type, Administration Route, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inovio Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments